Navigation
Market Outlook Stock Screener Dividend Calendar Event Calendar Rating of shares Markets News
Try free

Bellerophon Therapeutics

NASDAQ BLPH
$0.06 0.0000 0.0000%
Today share price
USA
Sector: Healthcare Industry: Health Care Equipment & Supplies
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 19 %
Market cap

Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.

687.48K
EV

Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
-6.03M
Beta

Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
-0.50
Shares

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
12.23M
YTD

Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
51.89 %

Upcoming events Bellerophon Therapeutics

All events
No upcoming events scheduled

Overview

Financials

Key Metrics

Dividends

Industry overview

Events

Stock chart Bellerophon Therapeutics

Stock analysis Bellerophon Therapeutics

Indicator Company Industry
P/E (LTM)

Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.

More
-0.06 50.84
P/BV (LTM)

Shows the ratio of the market price of the share to the current book value.

More
0.27 17.86
EV/EBITDA (LTM)

Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.

More
0.55 36.60
Net Debt/EBITDA (LTM)

A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.

More
0.61 0.81
ROE (LTM)

Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.

More
-313.46 18.00

Price change Bellerophon Therapeutics per year

3.66$ 10.37$
Min Max

Summary analysis Bellerophon Therapeutics

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Bellerophon Therapeutics

Revenue and net income Bellerophon Therapeutics

All parameters

Stock news Bellerophon Therapeutics

All news
5 June 2023 в 17:30

Bellerophon Therapeutics Shares Drop 84% After INOpulse Trial Misses Primary Endpoint

5 June 2023 в 17:25

Bellerophon Therapeutics Shares Drop 84% After INOpulse Trial Misses Primary Endpoint

5 June 2023 в 14:20

Bellerophon Therapeutics Phase 3 Trial for INOpulse Misses Primary Endpoint

5 June 2023 в 14:20

Bellerophon Therapeutics Phase 3 Trial for INOpulse Misses Primary Endpoint

5 January 2023 в 19:00

Bellerophon Therapeutics Shares Hit 52-Week High After License Agreement

5 January 2023 в 18:55

Bellerophon Therapeutics Shares Hit 52-Week High After License Agreement

5 January 2023 в 17:36

Bellerophon Therapeutics Shares Double After INOpulse License Deal

5 January 2023 в 17:35

Bellerophon Therapeutics Shares Double After INOpulse License Deal

27 September 2022 в 17:16

Bellerophon Therapeutics Shares Rise After FDA Accepts Trial Proposal

27 September 2022 в 17:16

Bellerophon Therapeutics Shares Rise After FDA Accepts Trial Proposal

20 December 2021 в 18:10

Bellerophon Therapeutics Shares Drop 21% After Friday Rise

20 December 2021 в 18:10

Bellerophon Therapeutics Shares Drop 21% After Friday Rise

17 December 2021 в 17:00

Bellerophon Therapeutics Sees Positive Data in Trial for Hypertension Treatment

17 December 2021 в 16:55

Bellerophon Therapeutics Sees Positive Data in Trial for Hypertension Treatment

About company Bellerophon Therapeutics

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its products include INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 2 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; that has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that is in Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension, pulmonary hypertension associated with pulmonary edema from high altitude sickness, and COVID-19 patients. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.
Address:
184 Liberty Corner Road, Warren, NJ, United States, 07059
Company name: Bellerophon Therapeutics
Issuer ticker: BLPH
ISIN: US0787713009
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 2015-02-13
Sector: Healthcare
Industry: Health Care Equipment & Supplies
Site: https://www.bellerophon.com

On which stock exchange are Bellerophon Therapeutics (BLPH) stocks traded?

Bellerophon Therapeutics (BLPH) stocks are traded on NASDAQ.

What is the ticker of Bellerophon Therapeutics stocks (BLPH)?

The stock ticker of Bellerophon Therapeutics’s stocks or in other words, the code is BLPH. The stocks are currently listed on the NASDAQ exchange.

In which sector and industry does Bellerophon Therapeutics (BLPH) operate?

According to the GICS (Global Industry Classification Standard) classification developed jointly by MSCI and Standard & Poor's, Bellerophon Therapeutics (BLPH) belongs to the «Healthcare» sector and the «Health Care Equipment & Supplies» industry.

In what currency are Bellerophon Therapeutics (BLPH) stocks traded?

Bellerophon Therapeutics (BLPH) stocks are traded on the NASDAQ exchange in dollars.

What is the price of Bellerophon Therapeutics (BLPH) stocks today?

The current price of Bellerophon Therapeutics stocks on 14.05.2024 is 0.0562 dollars. per share.

What is the dynamics of Bellerophon Therapeutics (BLPH) stocks from the beginning of the year?

Bellerophon Therapeutics (BLPH) quotes have increased by 51.89% from the beginning of the year up to 0.0562 dollars. per 1 stocks.

How much did Bellerophon Therapeutics (BLPH) stocks increase in мае 2024?

This month Bellerophon Therapeutics (BLPH) quotes have increased by 9.55% to 0.0562 dollars. per share.

How much are Bellerophon Therapeutics (BLPH) stocks worth?

Today, on October, 14.05.2024 Bellerophon Therapeutics’s (BLPH) stocks cost 0.0562 dollars..

What is the market capitalization of Bellerophon Therapeutics (BLPH)?

Capitalization is the market value of Bellerophon Therapeutics (BLPH) is calculated as the number of issued stocks multiplied on the current quotation price. Thus, on 14.05.2024, the market capitalization of Bellerophon Therapeutics (BLPH) is estimated at about 687475 dollars.